Article 42
Scope of the centralised marketing authorisation procedure
1.   Centralised marketing authorisations shall be valid throughout the Union.
2.   Centralised marketing authorisation procedure shall apply in respect of the following veterinary medicinal products:
(a)
veterinary medicinal products developed by means of one of the following biotechnological processes:
(i)
recombinant DNA technology;
(ii)
controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells;
(iii)
hybridoma and monoclonal antibody methods;
(b)
veterinary medicinal products intended primarily for use as performance enhancers in order to promote the growth of treated animals or to increase yields from treated animals;
(c)
veterinary medicinal products containing an active substance which has not been authorised as a veterinary medicinal product within the Union at the date of the submission of the application;
(d)
biological veterinary medicinal products which contain or consist of engineered allogeneic tissues or cells;
(e)
novel therapy veterinary medicinal products.
3.   Points (d) and (e) of paragraph 2 shall not apply to veterinary medicinal products consisting exclusively of blood components.
4.   For veterinary medicinal products other than those referred to in paragraph 2, a centralised marketing authorisation may be granted if no other marketing authorisation has been granted for the veterinary medicinal product within the Union.
